Alkermes ALKS State US Medicaid Rebates — Accounts Payable Current

Similar metrics at other companies

NAMSAccounts Payable Current

$5.42M-8.0%

SNAccounts Payable Current

$760.81M—

RXRXAccounts Payable Current

$12.67M-34.4%

OCAccounts Payable Current

$1.35B+7.7%

DTAccounts Payable Current

$7.92M-0.9%

EOSEAccounts Payable Current

$105.6M+166%

FAQ

What is Alkermes's state US medicaid rebates — accounts payable current?

Alkermes (ALKS) reported state US medicaid rebates — accounts payable current of $75.6M in Q2 2026.

How has Alkermes's state US medicaid rebates — accounts payable current changed year-over-year?

Alkermes's state US medicaid rebates — accounts payable current increased by 74.6% year-over-year, from $43.3M to $75.6M.

What does state US medicaid rebates — accounts payable current mean?

This metric represents the current liability owed to state government agencies for mandatory rebates associated with the sale of pharmaceutical products under the Medicaid Drug Rebate Program. It reflects the estimated financial obligation for products dispensed to Medicaid beneficiaries that have not yet been settled with the respective state authorities. This balance is a critical indicator of the company's short-term regulatory and financial commitments within the U.S. public healthcare market.